Potential missed opportunities to prevent ischaemic stroke: prospective multicentre cohort study of atrial fibrillation-associated ischaemic stroke and TIA

Duncan Wilson, Gareth Ambler, Clare Shakeshaft, Gargi Banerjee, Andreas Charidimou, David Seiffge, Mark White, Hannah Cohen, Tarek Yousry, Rustam Salman, Gregory Y H Lip, Keith Muir, Martin M Brown, H R Jäger, David J Werring, CROMIS-2 collaborators, Kirsty Harkness, Louise Shaw, Jane Sword, Azlisham Mohd Nor, Pankaj Sharma, Roland Veltkamp, Deborah Kelly, Frances Harrington, Marc Randall, Matthew Smith, Karim Mahawish, Abduelbaset Elmarim, Bernard Esisi, Claire Cullen, Arumug Nallasivam, Christopher Price, Adrian Barry, Christine Roffe, John Coyle, Ahamad Hassan, Caroline Lovelock, Jonathan Birns, David Cohen, L Sekaran, Adrian Parry-Jones, Anthea Parry, David Hargroves, Harald Proschel, Prabel Datta, Khaled Darawil, Aravindakshan Manoj, Mathew Burn, Chris Patterson, Elio Giallombardo, Nigel Smyth, Syed Mansoor, Ijaz Anwar, Rachel Marsh, Sissi Ispoglou, Dinesh Chadha, Mathuri Prabhakaran, Sanjeevikumar Meenakishundaram, Janice O'Connell, Jon Scott, Vinodh Krishnamurthy, Prasanna Aghoram, Michael Mccormick, Nikola Sprigg Paul O'Mahony, Martin Cooper, Lillian Choy, Peter Wilkinson, Simon Leach, Sarah Caine, Ilse Burger, Gunaratam Gunathilagan, Paul Guyler, Hedley Emsley, Michelle Davis, Dulka Manawadu, Kath Pasco, Maam Mamun, Robert Luder, Mahmud Sajid, Ijaz Anwar, James Okwera, Julie Staals, Elizabeth Warburton, Kari Saastamoinen, Timothy England, Janet Putterill, Enrico Flossman, Michael Power, Krishna Dani, David Mangion, Appu Suman, John Corrigan, Enas Lawrence, Djamil Vahidassr, Duncan Wilson, Gareth Ambler, Clare Shakeshaft, Gargi Banerjee, Andreas Charidimou, David Seiffge, Mark White, Hannah Cohen, Tarek Yousry, Rustam Salman, Gregory Y H Lip, Keith Muir, Martin M Brown, H R Jäger, David J Werring, CROMIS-2 collaborators, Kirsty Harkness, Louise Shaw, Jane Sword, Azlisham Mohd Nor, Pankaj Sharma, Roland Veltkamp, Deborah Kelly, Frances Harrington, Marc Randall, Matthew Smith, Karim Mahawish, Abduelbaset Elmarim, Bernard Esisi, Claire Cullen, Arumug Nallasivam, Christopher Price, Adrian Barry, Christine Roffe, John Coyle, Ahamad Hassan, Caroline Lovelock, Jonathan Birns, David Cohen, L Sekaran, Adrian Parry-Jones, Anthea Parry, David Hargroves, Harald Proschel, Prabel Datta, Khaled Darawil, Aravindakshan Manoj, Mathew Burn, Chris Patterson, Elio Giallombardo, Nigel Smyth, Syed Mansoor, Ijaz Anwar, Rachel Marsh, Sissi Ispoglou, Dinesh Chadha, Mathuri Prabhakaran, Sanjeevikumar Meenakishundaram, Janice O'Connell, Jon Scott, Vinodh Krishnamurthy, Prasanna Aghoram, Michael Mccormick, Nikola Sprigg Paul O'Mahony, Martin Cooper, Lillian Choy, Peter Wilkinson, Simon Leach, Sarah Caine, Ilse Burger, Gunaratam Gunathilagan, Paul Guyler, Hedley Emsley, Michelle Davis, Dulka Manawadu, Kath Pasco, Maam Mamun, Robert Luder, Mahmud Sajid, Ijaz Anwar, James Okwera, Julie Staals, Elizabeth Warburton, Kari Saastamoinen, Timothy England, Janet Putterill, Enrico Flossman, Michael Power, Krishna Dani, David Mangion, Appu Suman, John Corrigan, Enas Lawrence, Djamil Vahidassr

Abstract

Objective: We report on: (1) the proportion of patients with known atrial fibrillation (AF); and (2) demographic, clinical or radiological differences between patients with known AF (and not treated) and patients with newly diagnosed AF, in a cohort of patients who presented with ischaemic stroke or transient ischaemic attack (TIA) not previously treated with anticoagulation.

Design: We reviewed cross-sectional baseline demographic and clinical data from a prospective observational cohort study, (CROMIS-2).

Setting: Patients were recruited from 79 hospital stroke centres throughout the UK and one centre in the Netherlands.

Participants: Patients were eligible if they were adults who presented with ischaemic stroke or TIA and AF and had not been previously treated with oral anticoagulation.

Main outcome measures: Proportion of patients with known AF before index ischaemic stroke or TIA from a cohort of patients who have not been previously treated with oral anticoagulation. Secondary analysis includes the comparison of CHA2DS2-VASc and HAS-BLED scores and other demographics and risk factors between those with newly diagnosed AF and those with previously known AF.

Results: Of 1470 patients included in the analysis (mean age 76 years (SD 10)), 622 (42%) were female; 999 (68%) patients had newly diagnosed AF and 471 (32%) patients had known AF. Of the 471 patients with known AF, 68% had a strong indication for anticoagulation and 89% should have been considered for anticoagulation based upon CHA2DS2-VASc score. Patients with known AF were more likely to have a prior history of dementia (4% vs 2%, p=0.02) and had higher HAS-BLED scores (median 3 vs 2). CHA2DS2-VASc, other risk factors and demographics were similar.

Conclusions: About 1/3 of patients who present with stroke and have AF who have not been treated with oral anticoagulation have previously known AF. Of these patients, at least 68% were not adequately treated with oral anticoagulation.

Trial registration number: NCT02513316.

Keywords: anticoagulation; atrial fibrillation; stroke.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Distribution of HAS-BLED and CHA2DS2-VASc scores between patients with known AF versus those with newly diagnosed AF. AF, atrial fibrillation.

References

    1. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012;379:648–61. 10.1016/S0140-6736(11)61514-6
    1. Kirchhof P, Benussi S, Kotecha D, et al. . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962. 10.1093/eurheartj/ehw210
    1. Lip GY, Frison L, Halperin JL, et al. . Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;41:2731–8. 10.1161/STROKEAHA.110.590257
    1. Pisters R, Lane DA, Nieuwlaat R, et al. . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest 2010;138:1093–100. 10.1378/chest.10-0134
    1. Palomäki A, Mustonen P, Hartikainen JEK, et al. . Underuse of anticoagulation in stroke patients with atrial fibrillation - the FibStroke Study. Eur J Neurol 2016;23:133–9. 10.1111/ene.12820
    1. Johansson C, Hägg L, Johansson L, et al. . Characterization of patients with atrial fibrillation not treated with oral anticoagulants. Scand J Prim Health Care 2014;32:226–31. 10.3109/02813432.2014.984952
    1. Wilson D, Ambler G, Shakeshaft C, et al. . Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol 2018;17:539–47. 10.1016/S1474-4422(18)30145-5
    1. Lip GYH, Nieuwlaat R, Pisters R, et al. . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010;137:263–72. 10.1378/chest.09-1584
    1. Linn J, Wollenweber FA, Lummel N, et al. . Superficial siderosis is a warning sign for future intracranial hemorrhage. J Neurol 2013;260:176–81. 10.1007/s00415-012-6610-7
    1. Gregoire SM, Chaudhary UJ, Brown MM, et al. . The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology 2009;73:1759–66. 10.1212/WNL.0b013e3181c34a7d
    1. Wardlaw JM, Smith EE, Biessels GJ, et al. . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–38. 10.1016/S1474-4422(13)70124-8
    1. Tomlin AM, Lloyd HS, Tilyard MW. Atrial fibrillation in New Zealand primary care: prevalence, risk factors for stroke and the management of thromboembolic risk. Eur J Prev Cardiol 2017;24 10.1177/2047487316674830
    1. Xian Y, O’Brien EC, Liang L, et al. . Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation. JAMA 2017;317:1057–67. 10.1001/jama.2017.1371
    1. Kirchhof P, Ammentorp B, Darius H, et al. . Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). EP Europace 2014;16:6–14. 10.1093/europace/eut263
    1. Quinn GR, Severdija ON, Chang Y, et al. . Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation 2017;135 10.1161/CIRCULATIONAHA.116.024057
    1. Olesen JB, Lip GY, Lindhardsen J, et al. . Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ’real world' nationwide cohort study. Thromb Haemost 2011;106:739–49. 10.1160/TH11-05-0364
    1. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012;125:2298–307. 10.1161/CIRCULATIONAHA.111.055079
    1. Mant J, Hobbs FDR, Fletcher K, et al. . Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503. 10.1016/S0140-6736(07)61233-1
    1. Bath PM, Prasad A, Brown MM, et al. . Survey of use of anticoagulation in patients with atrial fibrillation. BMJ 1993;307:1045 10.1136/bmj.307.6911.1045
    1. Lip GYH, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. Journal of Thrombosis and Haemostasis 2016;14:1711–4. 10.1111/jth.13386

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa